Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Ypsomed Holding (YPHDF) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of Ypsomed Holding $215, price $437, upside -50.6%, quality 64 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? Yes
- Add to watchlist
YH
Broad data
Sep 24, 2026
Broad data
Sep 24, 2026
Ypsomed Holding
YPHDF · USStretched ValuationStrong overvaluation with only moderate quality.
!Fair value $215.49 · Strongly overvalued (−50.6%)
✓Quality 64/100
!Expensive Growth (revenue 5y +12.6 %/yr)
✓Highly profitable · 30.4% net margin (TTM)
!Low debt · negative free cash flow
!1.0% dividend yield · Watch coverage
✓Wide moat 83/100
Watch Ypsomed Holding for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
49‑month range $141.95 – $526.35 · fair‑value band $139.73 – $242.75 · the $436.55 price screens above the $215.49 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Company profile
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication in Switzerland, Europe, North America, and internationally. The company offers various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other related services.
Show more
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication in Switzerland, Europe, North America, and internationally. The company offers various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other related services. It offers contract manufacturing of infusion sets and reservoirs. The company markets its products to hospitals, doctors, pharmacies and patients via subsidiaries and distributors. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
Stock analysis
Ypsomed Holding (YPHDF) currently trades at $436.55, while our model-based Fair Value estimate is $215.49, 50.6% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $404.83 per share, and 2 of the 16 models we run sit above the $436.55 price.
Bear case: the Dividend Discount group reads lowest at $40.60, and 14 of the 16 models stay below the price. Evidence for this calculation is high.
Scenario range: $139.73 (bear) to $242.75 (bull), the price of $436.55 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 64/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Ypsomed Holding reported revenue of CHF 731M in FY2026 versus CHF 465M in FY2022, a compound +12.0%/yr. Reported net income was CHF 222M in FY2026, compounding +76.0%/yr from FY2022. FY2022 was a trough year, so the rate overstates the trend.
Key figures
Market cap $5.9B · P/E ratio 21.6 · P/S ratio 6.57 · EPS (TTM) $20.17 · Dividend yield 1.0% · Net margin 30.4% · Return on equity 31.1% · Return on assets (EBIT) 8.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 54 out of 100 (medium confidence).
What moves the price
The share trades about 13% below its 52-week high and 25% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −37% fair-value upside, at −51%, YPHDF screens richer than that median.
Fair Value models
Bear $139.73
Fair Value $215.49
Bull $242.75
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then ($8.04 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EPV
$177.21
$206.39
$231.57
74
Residual Income
$113.75
$145.70
$249.76
73
ROIC Compounder
$190.77
$239.91
$295.24
72
All 16 models by family
Earnings-Based
Graham-Dodd
$138.55
$462.20
$618.82
64
Lynch FV
$104.83
$149.76
$194.69
61
PEG = 1.0
$104.83
$149.76
$194.69
57
EPV
$177.21
$206.39
$231.57
74
Dividend Discount
Gordon GGM
$24.21
$48.23
$73.04
67
DDM Multi-Stage
$24.21
$40.60
$50.91
67
Multiples
P/E Multiple
$336.19
$448.26
$560.32
63
P/S Multiple
$176.17
$234.89
$293.61
58
P/B Multiple
$231.82
$309.09
$386.36
55
EV/EBIT
$280.41
$376.43
$472.45
66
EV/EBITDA
$308.83
$414.32
$519.81
67
EV/Revenue
$133.30
$193.70
$254.10
53
Asset-Based
NCAV (Graham)
$34.34
$46.02
$68.69
54
Economic Profit
Residual Income
$113.75
$145.70
$249.76
73
ROIC Compounder
$190.77
$239.91
$295.24
72
Growth Earnings
Growth-Adj P/E
$283.38
$404.83
$526.28
67
Notify me when YPHDF reaches fair value
Put YPHDF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
64/100
Of which business quality 62 · Market factors (momentum, volatility) 55
Profitability
74
Margins and returns on capital today
Quality Growth
68
Are margins and returns improving?
Cashflow
42
Earnings quality: real cash, not paper profit
Fin. Strength
75
Balance sheet, leverage, solvency risk
Investment
23
Disciplined investing over empire-building
Low Volatility
63
Calm price path (market factor)
Momentum
58
Price trend over the last 3–12 months (market factor)
52W Momentum
42
Distance to the 52-week high (market factor)
Net Issuance
81
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
53/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−2.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.6%
Start year 2021 (pandemic). Over 10 years: +8.1% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.6%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+78.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+77.5%
Dividend (yield on the price)1.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.77.4% vs 19.1%, picking up
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.0% → 34%
2026 sits 184% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Start year 2021 (pandemic)
YPHDF screens overvalued: fair value 51% below the price. Compare with Intuitive Surgical, Inc →
Compare Ypsomed Holding with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 185 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $406.63 | $348.72 | −14% |
| EssilorLuxottica Société anonyme EL | €144.60 | €159.06 | +10% |
| Becton, Dickinson and Company BDX | $178.07 | $104.73 | −41% |
| Medline Inc MDLN | $34.70 | $29.06 | −16% |
| Alcon Inc ALC | $63.94 | $40.13 | −37% |
| West Pharmaceutical Services, Inc WST | $375.65 | $137.81 | −63% |
| Sartorius Stedim Biotech S.A DIM | €208.20 | €54.82 | −74% |
| Straumann Holding STMN | CHF 89.80 | CHF 45.50 | −49% |
| Sartorius Aktiengesellschaft SRT | €206.50 | €42.05 | −80% |
| Solventum Corporation SOLV | $89.50 | $134.36 | +50% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Ypsomed Holding (YPHDF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $215.49 versus the last price from Sep 25, 2026 of $436.55, about −51% upside (overvalued).
What is the fair value of YPHDF?
Our model-based fair value for Ypsomed Holding is $215.49 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $436.55.
What is the quality score of YPHDF?
Ypsomed Holding has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ypsomed Holding (YPHDF)?
Our model-based price target is the fair value of $215.49 (as of Sep 24, 2026) from 16 valuation models. Cautious scenario $139.73, optimistic scenario $242.75. It is a calculation from audited fundamentals, not an analyst target.
What is the Ypsomed Holding stock forecast for 2026?
Our models put fair value at $215.49, about −51% upside versus the last price from Sep 25, 2026 of $436.55 (overvalued). Cautious scenario $139.73, optimistic scenario $242.75. The calculation is refreshed regularly with new filings.
What is the revenue of Ypsomed Holding (YPHDF)?
Ypsomed Holding reported trailing-twelve-month revenue of about CHF 731M (latest available figure, as of Sep 24, 2026).
Does Ypsomed Holding pay a dividend?
Ypsomed Holding currently shows a dividend yield of about 1.01% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Ypsomed Holding (YPHDF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ypsomed Holding it is $215.49 per share (as of Sep 24, 2026), against a price of $436.55. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Ypsomed Holding stock overvalued or undervalued in 2026?
As of Sep 24, 2026, YPHDF trades above its calculated fair value: price $436.55, fair value $215.49, a gap of about −51% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of YPHDF?
No. The price is what the market pays today ($436.55); the fair value is what the company's own numbers justify ($215.49). For Ypsomed Holding the two are $221.06 per share apart. That gap is exactly why we show both numbers side by side.
How much is Ypsomed Holding worth?
The market values Ypsomed Holding at about $5.9B (market capitalisation, as of Sep 24, 2026). Per share that is $436.55; our models calculate a fair value of $215.49 per share.
What do the bullish and bearish scenarios say about YPHDF?
Our models span a range for Ypsomed Holding: cautious scenario $139.73, base $215.49, optimistic $242.75 per share (as of Sep 24, 2026, price $436.55). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of YPHDF?
Ypsomed Holding trades at a price-to-earnings ratio of 21.6 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $215.49 is built from several models across several years. Other multiples: P/B 7.6, P/S 7.7, EV/EBITDA 17.6.
How solid is the balance sheet of Ypsomed Holding (YPHDF)?
Balance-sheet figures for Ypsomed Holding (as of Sep 24, 2026): return on equity 31.1%, debt of 0.15 per unit of equity. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is YPHDF from its 52-week high?
Ypsomed Holding trades at $436.55, about 13% below its 52-week high of $501.00 and 25% above the low of $348.70 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $215.49 is for.
Which stocks are comparable to Ypsomed Holding?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ypsomed Holding stock attractive at the current price?
The data as of Sep 24, 2026: price $436.55, calculated fair value $215.49 (−51%), Quality Score 64/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of YPHDF calculated?
We run Ypsomed Holding through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $215.49, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Ypsomed Holding itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ypsomed Holding (YPHDF)?
The latest price we hold is from Sep 25, 2026 and stands at $436.55. Our model-based fair value is $215.49, about −51% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ypsomed Holding right now?
The price sits above even our optimistic bull case ($242.75). The favourable scenario is already priced in. Solid but not exceptional quality (64/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Ypsomed Holding (YPHDF) come from?
Earnings per share at Ypsomed Holding grew +15.1 % a year from 2015 to 2026. Broken into its drivers: revenue per share +6.9 %, EBIT margin +6.7 %, tax rate +1.0 %, residual (interest, one-offs) −0.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Ypsomed Holding
How large is the market capitalisation of Ypsomed Holding (YPHDF)?
The market capitalisation of Ypsomed Holding is $5.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ypsomed Holding (YPHDF)?
The price-to-sales ratio of Ypsomed Holding is 6.57 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ypsomed Holding (YPHDF)?
Earnings per share at Ypsomed Holding are $20.17 (price ÷ EPS = P/E 21.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Ypsomed Holding (YPHDF)?
The dividend yield of Ypsomed Holding is 1.0% (payout 21.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Ypsomed Holding (YPHDF)?
The net margin of Ypsomed Holding is 30.4% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ypsomed Holding (YPHDF)?
The return on equity (ROE) of Ypsomed Holding is 31.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ypsomed Holding (YPHDF)?
On an EBIT basis the return on assets of Ypsomed Holding is 8.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ypsomed Holding (YPHDF)?
The operating margin of Ypsomed Holding is 26.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ypsomed Holding (YPHDF)?
Revenue at Ypsomed Holding is growing −13.3% versus a year earlier (3y avg +13.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Ypsomed Holding (YPHDF)?
Earnings per share at Ypsomed Holding are growing +51.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Ypsomed Holding (YPHDF) generate?
The free cash flow of Ypsomed Holding is −CHF 16.3M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Ypsomed Holding (YPHDF) carry?
The net debt of Ypsomed Holding is CHF 232M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Ypsomed Holding in the live analysis
One click puts Ypsomed Holding on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.